Industry Insights Logo

Part 3 of a 4-Part Series: Is In-House Pharmacy Capture the Overlooked Strategy to Growing Your 340B Program?

SPONSORED CONTENT

The 340B program is facing a period of unprecedented change. With the Inflation Reduction Act (IRA) and Medicare’s Maximum Fair Price (MFP) provisions set to take effect in 2026, covered entities can expect significant shifts—most notably, reduced drug reimbursement and

Read More »
Industry Insights Logo

Is Your 340B Partner a Good Fit? Look for These Signs

SPONSORED CONTENT

Whether it’s new manufacturer restrictions affecting script and data qualification, amended state laws or regulations, or updated audit guidelines, the 340B landscape is constantly evolving. So, it’s no surprise that managing an organization’s 340B program is not easy

Read More »
Industry Insights Logo

Verity Solutions Presents: 340B Outlook from Capitol Hill and the States

SPONSORED CONTENT

Location: Gaylord National Resort & Convention Center, Fort Washington, MD

340B stakeholders headed to the 340B Coalition Summer Conference 2025 can start their week learning the latest developments in

Read More »
Industry Insights Logo

Don’t Miss a Claim: How to Monitor Disqualified Claims in Your 340B Program

SPONSORED CONTENT

In today’s 340B environment, every claim counts. With increased oversight, tighter margins, and growing manufacturer restrictions, covered entities need to maximize their 340B savings by capturing every eligible claim. One often-overlooked opportunity lies in understanding and monitoring disqualified claims.

These are

Read More »
Industry Insights Logo

The Compliance Arms Race: Can Smaller Covered Entities Keep Up?

SPONSORED CONTENT

The 340B program has morphed into a battlefield of rules, audits, and reporting. For smaller covered entities (CEs), especially rural hospitals and community clinics, keeping pace feels like a losing race. While large health systems deploy entire

Read More »
Industry Insights Logo

A Neutral Clearinghouse: An Area of Potential Collaboration Between Covered Entities, Manufacturers and Payers

SPONSORED CONTENT

Drug manufacturers defend their unrelenting campaign to reform the 340B program by citing, among other things, the need to protect themselves from the problem of duplicate discounts.  Federal law affords such protection for drugs dispensed or administered to Medicaid

Read More »
Industry Insights Logo

Explore a Forward-Deployed Inventory Model for High-Cost Drugs

SPONSORED CONTENT

Time Inventory Management and 340B Clearinghouse

The 340B program has experienced significant changes and disruptions over the past five years, prompting both legislative and judicial action. On May 15, a federal judge rejected efforts by four manufacturers to impose rebate-only

Read More »
Industry Insights Logo

Separating AI Hype from Real Value in 340B Program Management

SPONSORED CONTENT

AI is everywhere—chatbots, smart assistants, predictive tools. But in 340B? The line between what’s useful and what’s just marketing is getting blurrier by the day.

We’ve seen AI do

Read More »
Industry Insights Logo

Keeping the Lifeline Strong: Why 340B Matters More Than Ever for Safety-Net Hospitals and Other Providers

SPONSORED CONTENT

Across America, safety-net hospitals stand as a lifeline for millions. These institutions serve patients who often have nowhere else to turn — individuals who are uninsured, underinsured, or living in communities where healthcare access is limited.

For hospitals operating on razor-thin margins, the 340B

Read More »
Industry Insights Logo

EMR Change Ahead: 340B Readiness Starts Now!

SPONSORED CONTENT

News of an electronic medical record (EMR) conversion often brings about palpable anxiety and anticipation as a covered entity (CE) or health system braces itself for an enormous amount of change and new and improved avenues for patient care. These

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live